Open in interactive viewer → charts, metric popovers & call review

Cipher's Courtroom Windfall Meets Its Medicaid Hangover

A confirmed arbitration award and a debt-free balance sheet give Cipher real optionality, but Natroba's Medicaid erosion and an empty M&A pipeline are the harder tests.
CPH.TO · Earnings Call · 2026-11-13

Cipher Pharmaceuticals reported a quarter that looks transformational at the net income line and merely flat at the revenue line. Net revenue was $12.7 million, essentially unchanged from a year ago. Net income jumped to $10.9 million, or $0.42 per diluted share, but most of that came from a legal recovery rather than operations. Adjusted EBITDA was $7.2 million, a 57% EBITDA margin, and the company ended with $15.3 million in cash before collecting another $5 million after quarter-end.

The real change is the arbitration award against Sun Pharma. In September, the New York Federal Court denied Sun's petition to partially vacate the award and affirmed Cipher's ownership of the disputed clinical data. Cipher recognized $2.3 million of other operating income, a $2.2 million recovery of legal fees inside SG&A, and $0.5 million of interest. It also received $5.7 million in October. That is a company-specific catalyst with a long tail: a 15% royalty on Canadian Absorica LD sales through 2040 has not yet been recognized in results.

The court denies the petition to partially vacate the arbitration award and affirm the award, including the declaration that Cipher is the rightful owner of clinical data in dispute.

Ryan Mailling, Unknown · 2026-11-13

This is precisely the item Cipher refused to book a year ago. On the November 2025 call, an analyst asked how the Sun litigation recovery would be accounted for. CFO Ryan Mailling called it a contingent asset that would not be recognized until there was certainty. CEO Craig Mull added that Cipher had not received payment and did not expect to record anything until the New York courts ruled. “We haven't received any payment, and I don't think that we will be recording any until we hear what the New York courts say.” — Craig Mull, CEO · 2025-11-07 The court has now spoken, which is why Q3 net income is not a clean read on the business.

Epuris Is the Quiet Engine; Natroba Is the Loud Question

The operating story is a tale of two products. Epuris, the Canadian isotretinoin franchise, grew 15% to $3.9 million and reached 48.7% market share. More importantly, public reimbursement is finally broadening. Craig Mull said public funding became effective August 17 in British Columbia, August 27 in Quebec, and October 1 in Alberta, with the majority of additional product listing agreements finalized. That is the public drug plan thesis moving from promise to actual listings, and it should widen the addressable market over time.

Natroba remains the problem child. U.S. product revenue for Natroba and its authorized generic fell 12% to $7.1 million, which management attributed to reductions in the number of covered lives under Medicaid programs. The sequential 14% increase is encouraging, but the analyst debate immediately turned to quality. Andre Uddin asked how much of the Q3 sequential lift came from initial Walmart stocking versus underlying prescription demand. Bryan Jacobs declined to quantify it, citing the sensitivity of the Walmart relationship and competitive reasons. “Talking about exactly the volume of the units that-- that is something we would want to divulge just because of that relationship with Walmart that is just started as well as for competitive reasons.” — Bryan Jacobs, Unknown · 2026-11-13 He did confirm the stocking program covers all Walmart stores, not a subset, which makes the revenue bump meaningful but hard to underwrite as recurring demand.

The head lice and scabies story has not changed: permethrin resistance is real, Natroba is clinically superior, and management is spending more on marketing to educate patients and prescribers. But this is not a new theme. Prior calls have covered the same resistance data and the same commercial challenge. The difference now is that Cipher is layering retail distribution and direct-to-patient channels on top of a Medicaid base that is shrinking. That may work, but it is a slower build than the arbitration headline suggests.

Business Development: More Advisors, Same Empty Chair

Cipher's three-pronged growth strategy remains acquisitions or in-licensing of complementary products, out-licensing Natroba and Epuris outside North America, and larger company acquisitions. The new pieces are a board addition and outside help. Rajiv DeSilva, with three decades of healthcare and M&A experience, joined the board in September. Cipher also engaged a consulting firm to assist with out-licensing and to help identify product acquisition targets.

What has not changed is the closing record. The company spent prior calls describing an advanced-stage acquisition that ultimately did not materialize, and the current call repeats that language. Craig Mull said Cipher is seeing a lot of activity and expects to get something done in the short term, but he refused to call anything imminent. “I know what my hopes are. But, I mean, I do not really wanna say, hey, something's imminent because then, if it was the other side, the vendor would be you know, in a better position for leveraging the price.” — Craig J. Mull, Likely CEO or Senior Executive · 2026-11-13 That is honest, but it is also the same message shareholders have heard for several quarters. The licensing efforts for Natroba outside the U.S. have likewise slipped from a 2025 expectation of an agreement by the end of 2026 to a current stance of receiving interest from multiple parties.

Capital allocation is the pressure point. Cipher is debt-free, has $65 million undrawn on its facility, plus a $25 million accordion, and is generating cash. The NCIB is restrictive, so management is considering a substantial issuer bid. If a deal is close, buybacks may pause; if not, the cash balance will keep building. The arbitration proceeds improve that flexibility, but they also raise the bar for what management does with it.

What Actually Changed

The quarter delivered two tangible positives: the arbitration award is now a cash-and-royalty reality rather than a contingent asset, and Epuris public reimbursement is live in three key provinces. Those are real. The negatives are equally clear: core revenue is flat, Natroba is still leaking Medicaid volume, and the business development pipeline has produced more conversation than transactions. The net income figure is flattered by legal recoveries, while adjusted EBITDA shows a stable but not growing specialty pharma platform.

For investors, Cipher is now a sum-of-parts and optionality story. The arbitration royalty through 2040 and the cash on hand provide a floor; the Epuris listings provide a modest growth engine; the Natroba retail and direct-to-patient push provides upside if it can offset Medicaid erosion. But the next leg depends on M&A execution, and on that front the company has consistently promised more than it has delivered. The courtroom win is bankable. The commercial turnaround is not yet.